Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients

Menesy, A; Ehab, Ahmed; Abbas, Neven

doi:10.21608/mjvh.2021.158275

Cited by 4 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the findings of Menesy et al (13) , we found that albumin levels rise significantly after DAA therapy of HCV, and this was statistically significant at the P value of 0.015., as it increased from 3.16 g/dl before therapy up to 3.38 gm/dl after therapy. In contrast Abdulhameed et al (19) reported a significant decrease in albumin levels after DAA therapy, however, that result was not clinically significant as both of the pre-treatment and post-treatment values were within the normal range.…”

Section: Discussionsupporting

confidence: 91%

“…The current study showed no significant change between pretreatment and post treatment levels regarding bilirubin level similar to the studies published by Menesy et al (13) , Shousha et al (15) and Russo et al (18) which revealed no significant change of bilirubin level after treatment with DAAs. On the other hand, Alhaddad et al (16) reported a significant decrease in serum bilirubin levels after DAA combined with ribavirin treatment (p < 0.001).…”

Section: Discussionsupporting

confidence: 91%

“…Liver enzymes ALT and AST improved significantly in all SVR patients in the current study with a P value 0.001. These results are consistent with those of Menesy et al (13) , researchers in Egypt looked at how 100 patients with chronic Hepatitis C responded to DAA treatment, and they discovered a substantial drop in hepatic transaminase levels and an improvement in the patients' BMIs and lipid profiles. With SVR in place, hepatic inflammation should decrease, which could account for this phenomenon.…”

Section: Discussionsupporting

confidence: 91%

“…Due to an inverse relationship between TPO production and hepatic fibrosis severity, elevated TPO levels may remain important for platelet recovery even after SVR has taken place (12) . While Menesy et al (13) found no significant difference between pre-and post-treatment haemoglobin levels (11.4 and 10.84 gm/dl, respectively), in this study there was a significant improvement of haemoglobin level 12 weeks after treatment with DAAs with a P value of 0. 010.…”

Section: Discussioncontrasting

confidence: 83%

See 3 more Smart Citations

Impact of Direct Acting Antivirals Therapy on Novel Fibrosis Index for Assessment of Hepatic Fibrosis in Comparison with AST to Platelet Ratio and Fibrosis-4 (FIB-4) Indexes in Egyptian Patients with Chronic Hepatitis C Infection in Correlation with Fibroscan

Allam

El-Karmouty

Kaisar

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Scarring or progressive fibrosis and cirrhosis develop over time as a result of chronic viral infection, which induces inflammation and tissue healing via deposition of extracellular matrix. There has been an increase in the sustained virological response (SVR) and the rate of eradication of HCV because of the effectiveness of directacting antiviral drugs (DAAs). Reduced hepatic fibrosis is associated with increased SVR rates. There are a variety of non-invasive fibrosis imaging, scoring, and marker methods: transient elastography, aminotransferase platelet ratio index (APRI), as well as fibrosis-4 (FIB-4) score. Objective: The purpose of this research was comparing the novel fibrosis index to APRI, (FIB-4) score and fibroscan in predicting the degree of hepatic fibrosis in Egyptian chronic HCV patients who were managed by DAAs. Patients and methods: 100 Egyptians with chronic HCV infection participated in a our 3-month long prospective Cohort research using the IFN-free DAA combination of Sofosbuvir and Daclatasvir ± Ribavirin. Results: There was significant regression of fibrosis with DAAs treatment in all patients achieving SVR by fibroscan, APRI and fib4. Novel fibrosis index is reliable and good tool in estimation of liver fibrosis in correlation to fibroscan, with the cutoff value in prediction of hepatic fibrosis stage 4 was >3.1 and has sensitivity of 81.5% while the specificity was 74.1%. Conclusion Novel fibrosis index has been found to be good reliable marker for assessment of liver fibrosis with high accuracy of predicting f4 fibrosis stage. There was significant marked reduction of fibrosis degree by fibroscan, APRI and FIB4 after DAAs treatment.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 83%

See 2 more Smart Citations

Impact of Direct Acting Antivirals Therapy on Novel Fibrosis Index for Assessment of Hepatic Fibrosis in Comparison with AST to Platelet Ratio and Fibrosis-4 (FIB-4) Indexes in Egyptian Patients with Chronic Hepatitis C Infection in Correlation with Fibroscan

Allam

El-Karmouty

Kaisar

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…There was no significant difference noted regarding pre and post treatment hemoglobin level which had mean values of 13.182 and 13.282 gm/dl before and after treatment respectively (P =0.44), this is similar to Menesy et.al study (13) that showed that there were no significant difference noted regarding pre-and post-treatment hemoglobin levels which had mean values of 11.4 and 10.84 gm/dl before and after treatment respectively. Conversely, El Sagheer et al (14) reported a significant decrease in hemoglobin level from 13.6 before treatment down to 12.7 g/dl after, Another study reported a significant change in hemoglobin level after DAAs treatment ( P < 0.001).…”

Section: Discussionsupporting

confidence: 82%

Study of the effect of direct acting antivirals (DAAs) on fibrosis in chronic hepatitis C patients using transient elastography

Mohammed¹,

Attia²,

Ebeid³

et al. 2021

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Back ground: As DAA agents are leading to enormous cure rates, so identifying and monitoring patients who remain at a high complication risk after achieving SVR continue to be a critical issue. Numerous validated methods for noninvasive measurement of liver fibrosis can be used in the management of HCV infection. Methods study: A total of 50 Egyptian chronic HCV patients eligible for treatment with DAAs were enrolled in this prospective study. All subjects selected from Virology Unit of Tropical Medicine Department, Faculty of Medicine, Beni-Suef University received DAAs (SOV DCV) the endpoint was a sustained virologic response at 12 (SVR12) weeks post-treatment. All participants were evaluated non-invasively by Liver Stiffness Measurement (LSM) by Fibro Scan before DAAs treatment, and 6 months post-treatment. Results: SVR achieved by DAAs therapy was 96 % and was associated with significant improvement (p ˂0.05) of non-invasive fibrosis markers (FIB-4, APRI score, and LSM by Fibro Scan) from baseline compared to 6 months post-treatment. Using fibro scan regression of fibrosis in 30/45 patients (66%). Liver inflammation and synthetic functions also improved on follow up 12w and 6m post treatment. Conclusion: Regression of Liver inflammation and fibrosis in chronic hepatitis C patients post treatment with SOF DCV.

show abstract

Neuropsychiatric and Laboratory Outcomes of Hepatitis C Treatment in an Early-Treated HIV Cohort in Thailand

Ocampo,

Sacdalan,

Pinyakorn

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Hepatitis C virus (HCV) coinfection may further compromise immunological and cognitive function in people with HIV (PWH). This study compared laboratory and neuropsychiatric measures across the periods of HCV seroconversion and direct-acting antiviral (DAA) therapy with sustained virologic response (SVR) among PWH who initiated antiretroviral therapy (ART) during acute HIV infection (AHI) and acquired HCV after 24 weeks of ART. Methods Participants from the RV254 AHI cohort underwent paired laboratory and neuropsychiatric assessments during regular follow-up. The former included measurements of CD4 + and CD8 + T-cell counts, HIV RNA, liver enzymes, and lipid profiles. The latter included the Patient Health Questionnaire-9 (PHQ-9), Distress Thermometer (DT), and a 4-test cognitive battery that evaluated psychomotor speed, executive function, fine motor speed and dexterity. The raw scores in the battery were standardized and averaged to create an overall performance (NPZ-4) score. Parameters of HCV-coinfected participants were compared across HCV seroconversion and DAA treatment groups. Results Between 2009 and 2022, 79 of 703 RV254 participants acquired HCV after ≥ 24 weeks of ART; 53 received DAA, and 50 (94%) achieved SVR. All participants were Thai males (median age: 30 years); 34 (68%) denied past intravenous drug use, and 41 (82%) had a history of other sexually transmitted infections during follow-up. Following SVR, aspartate transferase (AST) and alanine transaminase (ALT) decreased (p < 0.001), while total cholesterol, low-density lipoprotein, and triglycerides increased (p < 0.01). The median CD4+/CD8 + ratio increased from 0.91 to 0.97 (p = 0.012). NPZ-4 improved from 0.75 to 0.91 (p = 0.004). The median DT score increased from 1.7 to 2.7 (p = 0.045), but the PHQ-9 score remained unchanged. Conclusion HCV coinfection is common in this group of high-risk PWH, highlighting the need for regular screening, early diagnosis, and treatment. There was a modest improvement in the CD4+/CD8 + T-cell ratio and cognitive performance after DAA therapy in patients who achieved SVR. Future studies should examine potential neuropsychiatric impacts during early HCV infection as well as the longer-term neuropsychiatric outcomes after DAA treatment with SVR.

show abstract

Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients

Cited by 4 publications

References 18 publications

Impact of Direct Acting Antivirals Therapy on Novel Fibrosis Index for Assessment of Hepatic Fibrosis in Comparison with AST to Platelet Ratio and Fibrosis-4 (FIB-4) Indexes in Egyptian Patients with Chronic Hepatitis C Infection in Correlation with Fibroscan

Impact of Direct Acting Antivirals Therapy on Novel Fibrosis Index for Assessment of Hepatic Fibrosis in Comparison with AST to Platelet Ratio and Fibrosis-4 (FIB-4) Indexes in Egyptian Patients with Chronic Hepatitis C Infection in Correlation with Fibroscan

Study of the effect of direct acting antivirals (DAAs) on fibrosis in chronic hepatitis C patients using transient elastography

Neuropsychiatric and Laboratory Outcomes of Hepatitis C Treatment in an Early-Treated HIV Cohort in Thailand

Contact Info

Product

Resources

About